Abstract
Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have